Aurora Cannabis expands portfolio in Australia, N.Z.
Executive Summary
- Aurora Cannabis announced the launch of six new medical‑cannabis products in Australia and New Zealand, expanding its regional portfolio.
- The new offerings include four THC‑rich resin cartridges in Australia and three THC‑dominant flower varieties plus a balanced strain slated for Q1 FY 2027 in New Zealand.
- All products are manufactured at Aurora’s EU‑GMP and TGA‑GMP certified facilities in Canada, underscoring the company’s commitment to quality and regulatory compliance.
Key Details
- Australia – Resin Cartridges (launched this month):
- Chemango Kush – Indica, THC 780 mg/g, CBD < 10 mg/g
- Cosmic Cream – Indica, THC 780 mg/g, CBD < 10 mg/g
- Lunar Express – Indica, THC 780 mg/g, CBD < 10 mg/g
-
Soul Train Haze – Sativa, THC 780 mg/g, CBD < 10 mg/g
-
New Zealand – Flower Products (launched this month):
- Big Wave – Hybrid flower, THC 26 %, CBD < 1 %
- Night Ride – Indica flower, THC 29 %, CBD < 1 %
-
Half Moon – Hybrid flower (balanced), THC 9 %, CBD 13 % (expected Q1 FY 2027)
-
Manufacturing: All products derived from Aurora’s proprietary genetics and produced at EU‑GMP and TGA‑GMP certified facilities in Canada.
-
Strategic Rationale: Expansion supports Aurora’s “global medical growth strategy,” targeting Australia as one of its largest international markets and reinforcing commitment to the ANZ region.
-
Leadership Quote: Stanley Sack, interim Managing Director of MedReleaf Australia, emphasized continued investment and focus on high‑quality, diversified product formats to meet evolving patient needs.
Notable Quotes
“With Australia being one of our largest international medical cannabis market, both Australia and New Zealand remain a top priority for Aurora… Our focus on quality and reliable supply reflects our dedication to ensuring patients have meaningful access to the products they depend on.” – Stanley Sack, interim Managing Director, MedReleaf Australia.